SCHEMBL2876180

SCHEMBL2876180

NC1CC2CCC(N)(C1)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
TSHR P16473 1/20 0.42
NFKB1 P19838 1/20 0.42
STAT6 P42226 1/20 0.42
GRIN1 Q05586 1/20 0.42
GRIN2A Q12879 1/20 0.42
GRIN2B Q13224 1/20 0.42
GRIN2C Q14957 1/20 0.42
GRIN3A Q8TCU5 1/20 0.42
SLC47A1 Q96FL8 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
THRB P10828 2/20 0.40
POLB P06746 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2867784 0.98 LMNA (0.44) LMNASLC22A2SLC22A1GRIN2DGRIN3B
Methane SCHEMBL16654784 0.85 LMNA (0.37) LMNASLC22A2SLC22A1GRIN2DGRIN3B
SCHEMBL5807790 0.79
SCHEMBL19766530 0.79
Hydrochloric Acid SCHEMBL2876118 0.77 LMNA (0.60) LMNASLC22A2SLC22A1GRIN2DGRIN3B
SCHEMBL13556104 0.77 GRIN2D (0.63) LMNASLC22A2SLC22A1GRIN2DGRIN3B
Hydrochloric Acid SCHEMBL13736262 0.76
Hydrochloric Acid SCHEMBL6085232 0.75 LMNA (0.65) LMNASLC22A2SLC22A1GRIN2DGRIN3B
SCHEMBL301312 0.73
Hydrochloric Acid SCHEMBL23877623 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794120-B1 PEPTIDASE INHIBITORS NUADA LLC (US) 2012-04-11 EP disclosed
US-7842707-B2 Peptidase inhibitors NUADA, LLC (US) 2010-11-30 US disclosed
US-20080234292-A1 Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents NUADA, LLC 2008-09-25 US disclosed
EP-1794120-A2 PEPTIDASE INHIBITORS Royalty, Susan Marie (US) 2007-06-13 EP disclosed
WO-2006012441-A1 PEPTIDASE INHIBITORS ROYALTY SUSAN MARIE (US) 2006-02-02 WO disclosed
WO-2006012395-A2 PEPTIDASE INHIBITORS ROYALTY SUSAN MARIE (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234292-A1 Such as S)-(1-(1-Aminobicyclo[2.2.2]oct-4-yl)aminoacetyl)-2-cyanopyrrolidine; inhibitors of the enzyme dipeptidyl peptidase; antidiabetic agents DPP3, DPP4, DPP7 LMNA 4120/4885SLC22A2 1540/4885SLC22A1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.